Article

Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
Related Content
Long-term atropine use linked to higher risk of ocular complications in children
September 16th 2025

Long-term atropine use linked to higher risk of ocular complications in children

ROP: Treating and preventing blindness in preterm babies
September 16th 2025

ROP: Treating and preventing blindness in preterm babies

OCT changes with low-level red light therapy for myopia in children
September 16th 2025

OCT changes with low-level red light therapy for myopia in children

Managing a changing landscape of IRD pediatric cases
September 16th 2025

Managing a changing landscape of IRD pediatric cases

Tubulointerstitial nephritis and uveitis: A multidisciplinary approach to diagnosing a rare disease
September 16th 2025

Tubulointerstitial nephritis and uveitis: A multidisciplinary approach to diagnosing a rare disease

Japanese researchers link outdoor time to rapid increase in choroidal thickness
September 16th 2025

Japanese researchers link outdoor time to rapid increase in choroidal thickness

© 2025 MJH Life Sciences

All rights reserved.